Kura Oncology Inc

27 de ago. de 2026, 23:46 UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

26 de ago. de 2026, 23:41 UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

25 de ago. de 2026, 23:06 UTC

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

24 de ago. de 2026, 23:31 UTC

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

21 de ago. de 2026, 22:56 UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

20 de ago. de 2026, 23:16 UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

19 de ago. de 2026, 19:21 UTC

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

18 de ago. de 2026, 23:06 UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

17 de ago. de 2026, 22:51 UTC

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 de ago. de 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

13 de ago. de 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

12 de ago. de 2026, 23:01 UTC

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

10 de ago. de 2026, 19:43 UTC

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

7 de ago. de 2026, 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 de ago. de 2026, 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

5 de ago. de 2026, 19:26 UTC

Kura Oncology Inc shares are lower today amid ongoing market volatility. The company will report second-quarter 2026 results after the market close on August 12.

4 de ago. de 2026, 19:36 UTC

Kura Oncology Inc shares are higher today, continuing an upward trend since Monday. Broader market reactions follow a decline in U.S. core factory orders.

3 de ago. de 2026, 23:01 UTC

Kura Oncology Inc. shares are higher in after-market trading, reflecting notable gains since Monday's close, despite no specific news to explain the increase.

31 de jul. de 2026, 21:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable rise since Friday's close despite remaining below the 20-day moving average.

30 de jul. de 2026, 19:49 UTC

Kura Oncology Inc shares are higher Thursday, continuing a recent upward trend despite no specific news. The stock has rebounded from earlier session lows.

29 de jul. de 2026, 19:22 UTC

Kura Oncology shares are lower, extending a six-session decline amid market volatility following the Federal Reserve's interest rate decision.

28 de jul. de 2026, 20:03 UTC

Kura Oncology shares are lower despite positive Phase 1a trial results for darlifarnib plus cabozantinib, reflecting broader market pressures.

27 de jul. de 2026, 20:07 UTC

Kura Oncology shares are lower as the company reported Phase 1a results from its FIT-001 trial, showing a 33% to 50% response rate.

22 de jul. de 2026, 22:01 UTC

Kura Oncology Inc. shares are lower in after-market trading, reflecting unusual volatility amid broader market fluctuations from rising crude oil prices and geopolitical tensions.

21 de jul. de 2026, 19:36 UTC

Kura Oncology shares are higher Tuesday, amid positive market sentiment despite an earlier pullback. The stock remains below its 20-day moving average.

20 de jul. de 2026, 18:36 UTC

Kura Oncology shares are lower today, pulling back from earlier gains amid a broader market decline linked to rising Treasury yields and geopolitical tensions.